Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
Already Have An Account? Log in Now
Hemostatic Spray Powder TC-325 for Primary Endoscopic Treatment of Peptic Ulcer–Related Bleeding
abstract
This abstract is available on the publisher's site.
Access this abstract nowBACKGROUND
Upper gastrointestinal bleeding (UGIB) is a leading cause of morbidity and is associated with a 2 % - 17 % mortality rate in the UK and USA. Bleeding peptic ulcers account for 50 % of UGIB cases. Endoscopic intervention in a timely manner can improve outcomes. Hemostatic spray is an endoscopic hemostatic powder for GI bleeding. This multicenter registry was created to collect data prospectively on the immediate endoscopic hemostasis of GI bleeding in patients with peptic ulcer disease when hemostatic spray is applied as endoscopic monotherapy, dual therapy, or rescue therapy.
METHODS
Data were collected prospectively (January 2016 - March 2019) from 14 centers in the UK, France, Germany, and the USA. The application of hemostatic spray was decided upon at the endoscopist's discretion.
RESULTS
202 patients with UGIB secondary to peptic ulcers were recruited. Immediate hemostasis was achieved in 178/202 patients (88 %), 26/154 (17 %) experienced rebleeding, 21/175 (12 %) died within 7 days, and 38/175 (22 %) died within 30 days (all-cause mortality). Combination therapy of hemostatic spray with other endoscopic modalities had an associated lower 30-day mortality (16 %, P < 0.05) compared with monotherapy or rescue therapy. There were high immediate hemostasis rates across all peptic ulcer disease Forrest classifications.
CONCLUSIONS
This is the largest case series of outcomes of peptic ulcer bleeding treated with hemostatic spray, with high immediate hemostasis rates for bleeding peptic ulcers.
Additional Info
Disclosure statements are available on the authors' profiles:
Hemostatic Spray Powder TC-325 in the Primary Endoscopic Treatment of Peptic Ulcer–Related Bleeding: Multicenter International Registry
Endoscopy 2021 Jan 01;53(1)36-43, M Hussein, D Alzoubaidi, MF Lopez, M Weaver, J Ortiz-Fernandez-Sordo, P Bassett, JW Rey, BH Hayee, E Despott, A Murino, S Moreea, P Boger, J Dunn, I Mainie, D Graham, DK Mullady, DS Early, K Ragunath, JT Anderson, P Bhandari, M Goetz, R Kiesslich, E Coron, LB Lovat, R HaidryFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Gastroenterology
Hemospray (Tc-325), the most commonly used hemostatic powder, was used in a multicenter registry prospectively assessing 202 patients with peptic ulcer bleeding (most Forrest Ib 58% or Ia 19%). Immediate hemostasis rates (defined as within 5 minutes of Hemospray application) were 85% in Forrest I patients (87% in Ia and 85% in Ib). Overall, 30-day rebleeding was 17%; the 30-day all-cause mortality rate was 22%. A total of 50 patients (25%) received Hemospray as monotherapy, 101 (50%) as part of combination, and 51 (25%) as rescue therapy. There were no differences in outcomes among the three groups except for a lower 30-day mortality rate in the combination group (16%). These data further confirm Hemospray endotherapy feasibility and effectiveness in achieving immediate hemostasis. Its role as monotherapy in peptic ulcer bleeding remains unclear as the included IIa and IIb patients would not expect to benefit from Hemospray as no active bleeding lesions present for the product to bind to.
PuraStat (3D-Matrix Europe Ltd., France) is a novel synthetic self-assembling peptide that is a transparent gel formulation; it forms an extracellular scaffold matrix when activated by the change in pH that occurs upon contact with blood, thus providing a stable mechanical barrier over the bleeding site. Publications on its use have principally targeted intraprocedural bleeding, with some data suggesting accelerated healing properties. The present study is a single blinded randomized controlled trial of 101 patients undergoing endoscopic submucosal dissection (ESD) for 2- to 5-cm lesions treated in the esophagus or colon. Randomized patients received PuraStat or diathermy for grades 1/2 intraprocedural bleeding outside the immediate vicinity of the tip of the knife, or when the bleeding point was not easily accessible to diathermy. Routine end-of-procedure complete coverage of the resection base was achieved in all PuraStat patients. Significant reduction in the use of heat was noted in the PuraStat group compared with controls (49.3% vs 99.6%; P < .001). There were no differences in procedure length, time to achieve hemostasis, early rebleeding, or delayed bleeding up to 4 weeks. Complete wound healing at 4 weeks was more frequent in PuraStat patients (48.8% vs 25.0%; P = .02), a finding limited to colonic lesions. Small amounts of PuraStat were required (hemostasis = 0.43 mL per bleed, and prophylactic resection base coverage = 2.03 mL per patient). PuraStat was easy to apply and interfered with visibility in only 2 patients. The cost-effectiveness of this approach was not assessed. Additional adequately controlled studies are required to confirm these findings and better define their clinical relevance that could translate into a safer procedure with fewer post-ESD electrocoagulation syndromes and perforations. PuraStat is a promising topical agent, providing rapid hemostasis and potentially accelerating tissue healing.
References